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Tumor necrosis factor receptor-associated factors (TRAFs), initially identified as tumor necrosis factor receptor (TNFR) family-binding proteins, are important intracellular signaling components involved in apoptosis and immune cell signaling pathways [1] [2] [3] . TRAFs function as a scaffold that can link signaling receptors from outside of the cell to intracellular downstream signaling molecules [4] [5] [6] [7] [8] . The seven known TRAF proteins, TRAF1-TRAF7, play distinct roles in regulating immune responses, as well as in critical cellular signaling events, such as NF-kappaB, JNK, and apoptosis signaling pathways [2, 9, 10] . The common feature of TRAF proteins is the presence of a C-terminal homology domain of~180 amino acids (TRAF-C domain) and TRAF-N (coiled-coil domain) is followed by TRAF-C. This TRAF domain mediates protein-protein interactions [11] [12] [13] . The structures of TRAF domains of the proteins TRAF1-TRAF6 have Abbreviations ITC, isothermal titration calorimetry; LB, Luria-Bertani; RMSD, root-mean-square deviation; SEC, size-exclusion chromatography; SPR, surface plasmon resonance; TANK, TRAF family member-associated NF-kappaB activator; TRAF, tumor necrosis factor receptor-associated factor.
been elucidated [11, 12, [14] [15] [16] . TRAF domains are composed of seven to eight antiparallel b-strands folds (TRAF-C) and a coiled-coil region (TRAF-N). TRAF domains are known to form mushroom-like trimeric structures in solution. Another structural element of the TRAF proteins is the N-terminal RING domain that is critical for signal transduction [17, 18] . The involvement of TRAFs in the pathogenesis of cancer, autoimmunity, and inflammatory diseases makes them suitable targets for therapeutic intervention [19] .
Tumor necrosis factor receptor-associated factor 1 was originally identified as a TNFR2-interacting adaptor protein and considered as a unique TRAF-member, as it does not possess an N-terminal RING domain [18] . It is known that TRAF1 is involved in TNFR2 signaling in T cells as a negative regulator by directly interacting with TRAF2, which suppresses T cell receptor-mediated apoptosis [20, 21] . The proapoptotic function of TRAF1 in neuronal cell death was also reported recently, indicating that TRAF1 can be a novel therapeutic target for stroke treatment [22] . Most recently, a study reported the involvement of TRAF1 in the development of hepatic steatosis and related metabolic disorders, indicating its function as a positive regulator of insulin resistance [23] .
Tumor necrosis factor receptor-associated factor family member-associated NF-kappaB activator (TANK) has been identified as an inhibitor of TRAF2 function by direct interaction [24] . TANK interaction with TRAF2 blocks TRAF2 interaction with various signaling receptor molecules, including TNFR and LMP1 [25] . Therefore, it has been suggested that TANK might be a negative regulator of TRAF2-mediated NF-kappaB activation in the TNFR and CD40 signaling pathways. TRAF1, 2, and 3 are known targets of TANK, and their functions are regulated by direct interaction with TANK [24] [25] [26] . TANK recognition by TRAF has been investigated through structural studies of TRAF3/TANK peptide complex and biochemical studies with TRAF2 [25] . However, molecular details of TANK recognition by TRAF1 have not been elucidated so far. To understand the target recognition of TRAFs by the TRAF domain, structural studies of TRAF domains of TRAF2, TRAF3, TRAF5, and TRAF6 with various receptors have been performed [14] [15] [16] . Based on the interaction studies with TRAF2, two minimal consensus motifs for TRAF2 binding were identified: Px(Q/E)E motif as major and Px(Q/E)xxD motif as minor [14, 27] . Since then, different concensus minor motif was also proposed by the structural study of TRAF3 with various receptors including CD40 [28] , LMP1 [29] , and TANK [25] . Although the sequence identity between TRAF domains of TRAF1 and TRAF2 is high (~70%), and their interaction partners are almost identical, their functions are different, based on the interactions with their target molecules. To better understand TRAF1-and TRAF2-mediated signaling in the innate immune system and apoptosis, in this study, we report the crystal structure of TRAF1/TANK minimal peptide complex. Quantitative interaction experiments showed that the TANK peptide consisting of minor TRAF-binding motif can interact with both TRAF1 and TRAF2, exhibiting similar affinity of 20-30 lM. Our structural study revealed that that TANK binds to typical receptor-binding pocket on TRAF1 using a minor minimal consensus motif for TRAF binding, Px(Q/E)xT.
Materials and methods

Preparation of peptides
Four TRAF2-interacting minimal consensus motif including peptides, TNFR2p (QVPFSKEEC), CD30p (MLSVEEEG), Ox40p (PIQEE), and TRANCEp (QMPTEDEY), and one TANK peptide (SVPIQCTDKT) were synthesized and purified by Peptron (Dae-jeon, South Korea).
Protein expression and purification
Escherichia coli was used for the expression of TRAF1 TRAF domain (amino acid residues: 220-416) and TRAF2 TRAF domain (amino acid residues: 264-501). Expression and purification details for TRAF1 TRAF domain have been described in our previous study [12] . To obtain expression constructs of TRAF2, TRAF domain was cloned into pET24a vector containing the C-terminal hexahistidine (6xHIS) tag. The plasmid construct was transformed into BL21 (DE3) E. coli competent cells, followed by plating the cells onto Luria-Bertani (LB) media. The plate was incubated for 24 h at 37°C. Individual colonies were inoculated into 5 mL LB media for small-scale culture. Cultured cells were transferred to 1 L LB media for large-scale culture and incubated for 4 h at 37°C with shaking, after which expression was induced by treating the bacteria with 0.25 mM isopropyl b-D-thiogalactopyranoside for 20 h at 20°C. The bacteria were collected, resuspended, and lysed by sonication in 50 mL lysis buffer (20 mM TrisHCl pH 7.9, 500 mM NaCl, and 10 mM imidazole). The bacterial lysates were removed by centrifugation at 10 000 g for 30 min at 4°C. The supernatant of each sample was then applied to a gravity-flow column (Bio-Rad, Hercules, CA, USA) packed with 2 mL of Ni-nitrilotriacetic acid affinity resin (Qiagen, Hilden, Germany). One hundred milliliters of washing buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 60 mM imidazole) was used for removing unbound bacterial proteins. The target proteins were eluted from the column using an imidazole-containing elution buffer (20 mM Tris-HCl pH 7.9, 500 mM NaCl, 250 mM imidazole). Pure target proteins, verified using SDS/PAGE, were collected, and further purified by size-exclusion chromatography (SEC). Superdex 200 size-exclusion column 10/30 (GE Healthcare, Princeton, NJ, USA), pre-equilibrated with a solution of 20 mM sodium citrate pH 5.0 and 1 M NaCl, was used for the SEC experiment. The eluted target proteins (15-16 mL) were collected and concentrated to 5-6 mgÁmL À1 . The concentration was measured using a protein assay kit (Bio-Rad).
Sequence alignment
The amino acid sequences of TRAF domains of TRAF1 and TRAF2 were analyzed using CLUSTAL OMEGA (http:// www.ebi.ac.uk/Tools/msa/clustalo/).
Isothemal titration calorimetry
NanoITC (TA Instruments, New Castle, DE, USA) was used for isothermal titration calorimetry (ITC) experiments. TRAF domains of TRAF1 and TRAF2 proteins were dialyzed against PBS buffer, and the five lyophilized peptides, including TANK peptide (SVPIQCTDKT), were dissolved in the same buffer to minimize the heat of dilution values. Prior to titration, the protein samples and the peptide were centrifuged at 9000 g at 4°C for 5 min to remove any precipitants. For incremental injection in ITC experiments, 2 lL of a concentrated peptide solution (1 mM) was injected into a sample cell, containing 190 lL TRAF1 TRAF domain or TRAF2 TRAF domain at a concentration of~20 lM. All the titrations were carried out at 15°C with 25 injections at 160-s intervals. The area under each titration peak was integrated, plotted against the number of injections and fitted to a one-site independent binding model, using the software provided by TA instruments. Experimental data were subtracted from appropriate baselines acquired by injecting peptides into the buffer.
Surface plasmon resonance
Physical interactions between peptides and TRAF domain were analyzed by surface plasmon resonance (SPR) experiments. TRAF domain was immobilized on a nitrilotriacetic acid sensor chip, using a 6xHis-tag from Biacore T200 (GE Healthcare). First, the sensor chip surface was coated by injecting 100 mM nickel. Then, either TRAF1 or TRAF2 was diluted in PBS to a concentration of 100 lgÁmL À1 and injected at a rate of 10 lLÁmin À1 for 1 min for tandem immobilization on the nitrilotriacetic acid chip surface, resulting in around 3000 Response Unit after stabilization. Concentrations ranging from 1 to 100 lM of TANK peptide were prepared by dilution in PBS, and injected in the TRAF domain-coated flow channel at a flow of 30 lLÁmin À1 for 1 min, followed by a dissociation time of 300 s and regeneration with mixture of EDTA and guanidine HCl. Raw sensorgrams were double blanked by subtracting responses from reference flow channel and blank injection.
Crystallization, peptide soaking, and data collection
Crystallization of TRAF1 TRAF domain for peptide soaking was conducted at 20°C by the hanging drop vapor-diffusion method using a preidentified condition for the structural study of TRAF1 TRAF domain. The final crystals used for the X-ray diffraction study were grown on plates by equilibrating a mixture containing 1 lL of protein solution (5-6 mgÁmL À1 protein in 20 mM sodium citrate pH 5.0 and 1 M NaCl) and 1 lL of reservoir solution containing 1.38 M ammonium sulfate, 0.1 M CHES pH 9.3, and 200 mM NaCl against 0.3 mL of reservoir solution. The crystal grew to maximum dimensions of 0.1 9 0.2 9 0.4 mm in 3 days. The crystal was soaked at 100 lM TANK peptide-containing buffer for 24 h before freezing in liquid nitrogen. Data (3.2 A) were collected at the SB-II (5C) beamline at Pohang Accelerator Laboratory, Republic of Korea. Data processing and scaling was carried out using HKL3000 [30] .
Structure determination and analysis
The structure was determined by the molecular replacement phasing method using PHASER [31] . The TRAF1 structure recently solved by our group (PDB code: 5E1T) was used as a search model. Model building and refinement were performed in COOT [32] and PHENIX [33] , respectively. The quality of the model was checked using PROCHECK and was found to be reasonable [34] . It was found that 97% of the residues were shown to be located in the most favorable region, while 3% were in the allowed regions of the Ramachandran plot. The data collection and refinement statistics are summarized in Table 1 . Ribbon diagrams and molecular surface representations were generated using PYMOL [35] .
Results
TANK binds to TRAF1 and TRAF2 for signaling control
Among the seven TRAF proteins, TRAF1 is unique because of the absence of N-terminal RING domain (Fig. 1A) , and TRAF1 TRAF domain has the highest sequence homology with TRAF2 TRAF domain (~70%; Fig. 1B) . Consequently, TRAF1 shares various common interaction targets with TRAF2. Due to the importance of TRAF functions in direct interaction with different receptors and intracellular signaling molecules, structural and biochemical analysis of the TRAF domain, which is the main protein-protein interaction domain in the TRAF family, was essential to determine how the TRAF family can accommodate various receptors using a limited interaction interface. Interaction studies between the TRAF domain and various target molecules, including TNFR2, CD40, CD30, and LMP1, were performed with representative TRAF family proteins, TRAF2 and TRAF6, and recently with TRAF3 and TRAF5. These studies revealed that TRAF 2, 3, and 5 have a unique interaction site in their TRAF domain that can accommodate two binding motifs of interacting molecules, namely major motif and minor motif (Fig. 1C) , while the TRAF6 interaction motif was PxExxO (acidic or aromatic) [14] [15] [16] .
Tumor necrosis factor receptor type 1-associated death domain protein (TRADD) is a famous death domain-containing adaptor molecule that mediates interactions between TNFR1 and downstream molecules in apoptosis signaling and NF-kappaB activation [36] . TRADD also can inhibit TRAF2-mediated apoptosis by direct interaction with TRAF2. TRADD binds to TRAF2 in a region different form that where all other receptors bind (Fig. 1D) [37] . All residues in TRAF2 that are involved in the interaction with various receptors and TRADD are also well-conserved in TRAF1 (Fig. 1B,D) . The only amino acid from TRAF2 that is not conserved in TRAF1 is S454, which is replaced by A369 in TRAF1. This residue was found to be involved in the interaction with both various receptor and TRADD (Fig. 1D) .
Quantitative interaction analysis of TRAF1 and TRAF2 with TANK
To compare binding affinities and characteristics of TRAF1 and TRAF2 and to better understand TRAF1-and TRAF2-mediated signaling, we analyzed the interactions between TRAF1 or TRAF2 and several receptor peptides and adaptor peptides: TNFR2 (QVPFSKEEC), CD30 (MLSVEEEG), Ox40 (PIQEE) TRANCE (QMPTEDEY), and TANK (SVPIQCTDKT). All the peptides contain TRAF2-or TRAF6-interacting minimal consensus motifs. However, only TANK peptide (SVPIQCTDKT) seemed to bind TRAF1 and TRAF2 in the initial binding screening. TANK is known as an endogenous protein inhibitor of TRAF2 function that can directly interact with TRAF2 and block the binding of other signaling molecules that are essential for proper signaling events. Although it has been suggested that TANK can interact with TRAF1, 2, and 3 using qualitative analysis, quantitative analysis of their interaction was reported from TRAF3 and TANK interaction studies [25] . Recently, when we reported the structure of TRAF domain of TRAF1, we introduced the tentative in vitro interaction between TRAF1 and TANK [12] . Based on these preliminary binding data, we thoroughly analyzed the interaction between TRAF domains of TRAF1 or TRAF2 and TANK peptide (SVPIQCTD KT) using ITC and SPR. TANK peptide (1 mM) was titrated into 20 lM of TRAF 1 or TRAF2 with 25 injections for incremental ITC experiments ( Fig. 2A,B) . All the ITC experiments were performed at 15°C. In both cases, the released heat was in agreement with ideal interaction values, indicating the existence of a single type of binding site without distinct co-operativity in the interaction. Control titration, performed without binding proteins, was measured and subtracted from the real and the dissociation constant were 14 lM for TRAF1 and 16 lM for TRAF2, indicating that the TANK peptide interacts with both TRAF1 and TRAF2 with similar affinities ( Fig. 2A,B) . For the SPR experiment, each purified 6xHis-tagged TRAF1 and TRAF2 was coupled with Ni-nitrilotriacetic acid sensor chips using a His-tag affinity system. Different concentrations of the TANK peptide, from 1 to 100 lM, were analyzed for their binding with TRAF1 or TRAF2. As shown in Fig. 2C ,D, both TRAF1 and TRAF2 showed clear concentrationdependent interactions. The analyzed kinetics and affinity parameters were similar for both TRAF1 and TRAF2. K D values of 27.9 lM for TRAF1 interaction and 27 lM for TRAF2 interaction were obtained from the SPR experiments.
Crystal structure of TRAF1 TRAF domain/TANK peptide complex
Because the designed TANK peptide that contains TRAF-binding consensus motif tightly binds to TRAF1 and TRAF2, we investigated how TRAF1 and TRAF2 is recognized by TANK by solving the complex structure and comparing the protein interaction interface with previously reported structures of TRAF and peptides from various receptors. During this process, solubilized TRAF1 with high salt (1 M NaCl) and low pH (pH 5) was crystallized. To obtain the complex structure, TRAF1 crystals were soaked with various concentrations of TANK peptides at different time scales. The crystal soaked in 100 lM TANK peptide for 24 h diffracted to 2.8 A, and density of the peptide was clearly detected after solving the structure by molecular replacement using PHASER. The structure was refined to a R work = 25.5% and R free = 29.9%. There was one trimer (three monomers) in the asymmetric unit, chain A, chain B, and chain C, and three molecules related by near perfect threefold symmetry (Fig. 3A) . The structures of the three chains are nearly identical, having a root-mean-square deviation (RMSD) of 1.21 between the A and B chain, 1.26 between the B and C chain, and 1.48 between the A and C chain. Although the length and clearance of electron densities for peptides were different, three peptides (one peptide per each chain) were detected in the trimeric structure of TRAF1 TRAF domain (Fig. 3A) . Among the three peptides, TANK peptide in chain C was the most clearly modeled one with the longest length (Fig. 3B,C) . Among the designed TANK peptide, SVPIQCTDKT and SVPIQCTD were modeled, whereas the KT part at the C terminus was not modeled because of missing density values (Fig. 3C) . Previous structural studies of TRAF2 and various peptides from the receptor complex revealed that Q or E is the most conserved amino acid and denoted P 0 or the zero position of the TRAFbinding motif. Therefore, the labeling strategy for our TANK peptide was S (P À4 ), V (P À3 ), P (P À2 ), I (P À1 ), Q (P 0 ), C (P 1 ), T (P 2 ), and D (P 3 ). It is known that there are two minimal consensus motifs for TRAF1, 2, 3, and 5 binding: Px(Q/E)E motif as major and Px(Q/ E)xxD motif as minor. The side chains of P À2 , P 0, and P 1 from peptides, which contain the major TRAF2-binding motif, were critical for the interaction with TRAF, while the side chains of P À2 , P 0 and P 3 were critical for the TRAF interaction by peptides that contain the minor TRAF2-binding motif. Several studies also showed that the PxQxT motif might be important for binding with TRAF, whereas D on the minor consensus motif PxQxxD, is not important. Importance of PxQxT motif was suggested by structural studies of TRAF3 with various receptors, including CD40, LMP1, and TANK. Since the TANK peptide contains a minor TRAF-binding consensus motif, participation of the side chains of P À2 , P 0 , and P 3 in the interaction with TRAF1 was expected. The complex structure, however, showed that side chains of P 0 (Q), P 1 (C), and P 2 (T) were involved in the TRAF1 interaction (Fig. 3C,D ). Q at P 0 position formed a hydrogen bond with S368 of TRAF1. C and T at P 1 and P 2 positions, respectively, form hydrogen bonds with D314 of TRAF1. D at P 3 position, which was expected to participate in the interaction with R308 and Y310 of TRAF1, did not participate in the interaction in our structure. Because D at P 3 position was located at one end, the side chain of D at P 3 position might be located at another position, where the side chain was tilted to R308 and Y310 of TRAF1 (Fig. 3E,F) . In this alternative structure, side chain of D at P3 position was far from R308 and Y310 (5.2 and 4.8
A away from R308 and Y310, respectively), and could not participate in the interaction. To analyse the structural changes of TRAF1 upon binding of TANK peptides, we superimposed previously solved TRAF1 structure with currently solved TRAF1/TANK complex structure. Structural comparison showed that serine triad (S368, A369, and S370) containing loop is flexible and moved toward TANK peptide upon binding to TANK peptide. This movement is caused by forming hydrogen bond between P 0 :Q on TANK peptide and S368 on TRAF1 (Fig. 3G) .
Comparison of interaction of minor binding motif to TRAFs
Two available complex structures that show minor motif interactions in the TRAF domains are TRAF2/LMP1 [38] and TRAF3/TANK [25] complexes. Based on these two structures, the minor TRAF-binding motif, PxQ(E) xxD, has been identified. To compare structural similarity, current complex structure was superimposed with TRAF2/LMP1 and TRAF3/TANK complexes. Although each TRAF protein superimposed well with a RMSD of 0. 9 A between TRAF1 and TRAF2, and 1.1 A between TRAF1 and TRAF3, topology of bound peptides were found to be different especially at P 2 and P 3 positions (Fig. 4A) . Pair-wise structural alignments between the TRAF1/TANK complex and other TRAF/ peptide complexes showed that P 2 and P 3 positions of TANK peptide were not well-superimposed although P À4 , P À3 , P À2 , P À1 , P 0 , and P 1 superimposed almost identically (Fig. 4B,C) . Analysis of protein-peptide interface revealed that amino acids from TRAF that were involved in the interaction with peptides were slightly different in each complex. In the TRAF3 and TANK interaction, the first and last serine residues (S518 and S520) from serine triad and YD patch (Y460 and D462) of TARF3 were involved in the interaction with TANK peptide (Fig. 4B,  D) . However, the second and last serine residues (S454 and S455) and YD patch (Y395 and D399) of TRAF2 were involved in the interaction with LMP1 peptide (Fig. 4C,D) . In the TRAF1 recognition by TANK revealed by the current structure, only the first serine residue (S368) from serine triad and D from YD patch (D314) of TRAF1 participated in the interaction with TANK. D314 of TRAF1 also formed a stable hydrogen bond with a side chain of C from TANK at P 1 position. This interaction pattern detected in the interaction between TRAF1 and TANK was also the same when a tentatively modified structure, whose TANK peptide is modified to an alternative position, was used for interaction analysis (Fig. 4E ).
Discussion
The seven identified TRAF family proteins, TRAF1-TRAF7, are important adaptor molecules for important intracellular signaling processes, especially in apoptosis and immune cell signaling pathways. Various receptors including TNFR2, CD40, RANK, and CD30 directly bind to TRAF proteins for controlling proper signaling events. All TRAF proteins, except TRAF7, contain the TRAF domain that mediates protein-protein interaction.
The TRAF family member-associated NF-kappaB activator has been identified as a competitive intracellular inhibitor of TRAF2 function by interfering in the interaction of TRAF with various receptors, as it has a similar TRAF-interaction interface. TRAF2-TANK interaction negatively regulates TRAF2-mediated NFkappaB activation in the TNFR and CD40 signaling pathways. In vivo TANK interaction and inhibition studies have been done with TRAF2 [24] . In vitro studies of TANK recognition studies have been mostly done through structural studies of the TRAF3/TANK peptide complex [25] . TRAF1, unique member among TRAFs that does not possess the N-terminal RING domain, shows an antiapoptotic function in TNFR2 signaling in immune cells by direct interaction with TNFR2 [39] , as well as a proapoptotic function in neuronal cell death [22] . A recent study also suggested TRAF1 function as a possible positive regulator of insulin resistance and hepatic steatosis [23] . Although there is some indication of the involvement of TANK in TRAF1-mediated signaling by direct interaction with TRAF1, molecular and functional details of TANK recognition and interaction with TRAF1 have not been studied. In this study, we analyzed the quantitative interaction between TANK peptide and TRAF1 or TRAF2 using ITC and SPR, to analyze and compare binding affinities and characteristics of TANK interaction with TRAF1 and TRAF2. ITC experiments revealed that TANK could interact with both TRAF1 and TRAF2 with a K D of 14 lM for TRAF1 and 16 lM for TRAF2. SPR experiments also showed that TANK peptide interacts with both TRAF1 and TRAF2 with a K D of 27.9 lM for TRAF1 interaction and 27 lM for TRAF2 interaction. These interaction studies indicated that the TANK peptide can interact both TRAF1 and TRAF2 with micro molar range and affinity for TRAF1 and TRAF2 is almost same. Previous affinity analysis showed that K D for TRAF3 and TANK interaction was 23.9 lM, indicating that TANK interacts with TRAF1, TRAF2, and TRAF3 with similar affinity [25] . According to TRAF2 interaction studies with various receptor peptides by ITC experiment, TRAF2 interacts with TNFR2 (K D = 0.5 lM), CD30 (K D = 40 lM), CD40 (K D = 60 lM), and LMP1 (K D = 1.9 lM) [38, 40] . Therefore, the affinity between TRAF2 and TANK is higher than TRAF2/CD30 and TRAF2/CD40 interaction, and lower than TRAF2/TNFR2 and TRAF2/ LMP1 interaction. Recognition of various receptors and intracellular signaling molecules by the restricted binding sites of TRAFs is particularly interesting in this field of TRAF-mediated signaling. Although the sequence identity between TRAF1 and TRAF2 TRAF domains is the highest among the TRAF family and they share many binding partners, the functions of and those in TRAF2 involved in the LMP1 interaction (C) are indicated. H-bonds are shown as black-dashed lines. Amino acid position on the TANK labeled as P À4 , P À3 , P À2 , P À1 , P 0 , P 1 , P 2 , and P 3 are shown. (D, E) Close-up view of P 0 , P 1 , P 2 , and P 3 position of the three peptide complexes. The residues on TRAFs that are critical for binding with peptides are indicated at the proper positions. H-bonds and distance are shown as black-dashed lines and numbers colored in black (TRAF1/TANK), cyan (TRAF3/TANK), and green (TRAF2/LMP1). The structure of alternative TANK peptide bound to TRAF1 TRAF domain was also compared with TRAF3/TANK and TRAF2/LMP1 complexes (E).
TRAF1 and TRAF2 in regulating several signaling pathways are different. Among the several residues that are known to be participated in the interaction with various receptors, S454 on TRAF2 (A369 on TRAF1) is not conserved between TRAF1 and TRAF2. This residue, therefore, might be important to decide the function of TRAF1 and TRAF2.
Previous structural studies revealed that two minimal consensus motifs for TRAF2, TRAF3, and TRAF5 binding were identified: Px(Q/E)E motif as major and Px(Q/E)xxD motif as minor [14] . A novel TRAF6-binding consensus motif, PXEXX(F/W/Y)(D/E), was also identified [16] . After these major and minor consensus motifs were defined based on structures of TRAF2 and peptides from receptors, different consensus motifs were proposed soon after. Several structural studies described a consensus sequence PxQx(T/S) for TRAF3 binding to CD40, CD30, LMP-1, and TANK. These structure and mutagenesis studies indicated that conserved Thr on PxQxT motif is essential for binding to TRAF, whereas Asp209, which would be conserved in the minor consensus motif PxQxxD, is not important. Since receptor recognition sites on TRAF2 and TRAF3 are conserved with TRAF1, recognition of various receptors by TRAF1 is suggested to follow a mechanism similar to that of TRAF2 and TRAF3, while the nonconserved TRAF4 may have an entirely different recognition site [11] . To analyze the recognition of TANK by TRAF1, in this study, we solved the complex structure of TRAF1 and TANK peptide (SVPIQCTDKT), which contains the minor TRAF-binding motif. Our structure revealed that the topology of TRAF1-bound TANK peptide was different, especially in the P 2 and P 3 positions in LMP1 and TANK peptides, which are known from the previously solved structure of TRAF2/LMP1 and TRAF3/TANK complexes. Our TRAF1/TANK peptide structure showed that T at P 2 position formed a stable hydrogen bond with D314 on TRAF1, while D at P 3, which was considered as an important interacting residue on the minor TRAF-binding motif, was not involved in any interaction with TRAF1, thus indicating that PxQxT motif on TANK is recognized by a typical receptor-binding site of TRAF1. This recognition is similar with the interaction of TRAF3 by various receptors such as CD40, LMP1, and TANK. Thus, our structure of TRAF1/TANK complex reveals that TANK recognizes TRAF1 using PxQxT motif rather than PxQxxD motif.
